1. E-mail: joanne.livermore@liverpool.ac.uk
Date of Birth: 30.05.1980
Nationality: British
Joanne Louise Livermore
Education
PhD
“Development of a Non-Mammalian Host to Investigate Virulence and
Gene Expression of Aspergillus fumigatus and Efficacy of Antifungal
Drugs”
Co supervised by Dr Peter Warn and Professor David Denning
June 2010
BSc (Hons) First Class, Biomedical Science
Manchester Metropolitan University 1998-2004
A Level (Biology, Chemistry, General Studies, Mathematics)
GCSE (Biology, Chemistry, English Language/Literature, French,
Geography, Latin, Mathematics, Physics)
Bury Grammar School for Girls 1991-1998
Academic Achievements
Thomas. J. Walsh Mycology Award
Focus on Fungal Infections, San Diego 2007
Student Prize
Manchester Metropolitan University 2004
Professional Experience
Teaching for Researchers
University of Liverpool October 2015 – April 2016
PRINCE2 Foundation in project management
University of Liverpool September 2014
Level 5 Award in Management,
Institute of Leadership and Management June 2010
Biotechnology Young Entrepreneurs Scheme Oct 2007
Graduate Teaching Assistant Training Sept 2007
Employment History
University of Liverpool 2012-Present Day
Project Manager
(Antimicrobial Pharmacodynamics and Therapeutics Group)

2. • Project management of several long and short term projects including
F2G novel anti-microbial drug development, neonatal bacterial sepsis,
AIDA optimal dosing of off patent antibiotics, MRC cryptococcal
meningitis, AiCuris drug development programme.
• Line management of several project staff including visiting academics,
collaborators and students.
• Supervision of a PhD student.
• Co-ordinate and manage the program of experimental pharmacology to
ensure it is delivered in an efficient and timely manner.
• Accountable for the design, organisation and delivery of laboratory
animal models of infection.
• Accountable for the co-ordination and organisation of hollow fibre
models of infection.
• Develop medium-to-long term plan of work for each project.
• Accountable for the organisation and co-ordination of downstream
analysis of experimental samples by other team members.
• Liaise and collaborate with academic and commercial groups to deliver
pre-clinical methodology, results and reports.
• Overall responsibility to manage and monitor pre-clinical
experimentation to current Home Office legislation (staff training,
supervision of newly trained staff, competencies)
• Write and update COSHH and Risk assessments for the laboratory.
• Keep accurate records using paper and computer-based systems.
Provide internal and external staff and collaborators with a central point
of contact for all projects.
• Oversee budget management for several grants including liaising with
finance as necessary.
• Chair and contribute to laboratory, animal and planning meetings.
• Conduct technical staff PDRs.
• Deal with standard problems and help colleagues resolve their
concerns about progress in research.
• Collate and present data for further analysis and/or publication.
• Meticulous laboratory techniques and the ability to troubleshoot.
• Ensure that all procedures/ processes are conducted according to
statutory requirements as specified by the School, Faculty and
University.
• Collate and present data at national and international conferences by
poster or oral presentation.
• Write manuscripts for peer reviewed publication.
• Co-ordinate meetings, conferences and training programs.
• Complete study costings for research and commercial projects.
• Accountable for communication feeds such as group website and
twitter feed.

3. The University of Manchester 2009-2012
Research Assistant
(Translational Medicine)
Working within the pre-clinical animal team, I was responsible for ensuring all
experimental protocols, health and safety guidance and data sheets were
generated. I was responsible for ensuring all pre-clinical animal work was
completed within specified time lines. I worked flexibly to accommodate
dosing at unsociable hours. I trained staff and students in areas such as
qPCR, in vivo techniques and working with invertebrates. I completed projects
such as neonatal Candida meningoencephalitis and cryptococcal meningitis in
rabbits.
The University of Manchester 2005-2009
PhD Student
(Translational Medicine)
I was responsible for ensuring I completed my PhD to the highest standard. I
completed training in a number of techniques both in vivo and in vitro. I
assisted the animal facility with technical support during busy times and out of
hours. My PhD investigated the use of invertebrates as an alternative model
for studying infectious diseases.
Royal Bolton Hospital NHS Trust 2000-2005
Biomedical Scientist
(Histopathology Department)
Initially I was a trainee Biomedical Scientist. I worked full time within the
Histopathology Department and attended Manchester Metropolitan University
one day per week. During my time within Histopathology I assisted the
pathologist in cut up procedures, processed tissue samples, embedded and
sectioned tissues. I carried out special staining techniques such as Gram
stain, periodic acid schiffs (PAS), Grocott-Gomori Methenamine Silver GMS)
and ziehl-neelson (ZN). I also carried out immunohistochemistry techniques. I
was trained in microscope use. I was responsible for ensuring all my training
was up to date and completed when I finished my degree. I qualified as a
Biomedical Scientist in 2004.
Training Courses Attended: Teaching for Researchers, Communicating
Expert Research for Impact, PRINCE2 foundation stage, Introduction to Good
Clinical Practice, Managing Biosafety in the Laboratory, Safe working with
GMOs, Risk Assessment Workshop for Lab-based Staff, Project
Management, Researchers Into Management, Principles of Risk Assessment,
Developing the Postgraduate Manager, Ethics and Morality, Effective
Presentations, Writing Scientific Abstracts, Effective Academic Writing,
Bioimaging Workshop, Real time PCR Training Workshop, Time Management
Skills.

4. Home Office Licence Modules 1-5 (Mouse, Rat, Rabbit, Hamster, Cotton rat
and Guinea Pig)
References
Professor William Hope,
Antimicrobial Pharmacodynamics and Therapeutics,
Department of Molecular and Clinical Pharmacology,
University of Liverpool,
1.09 Sherrington Building,
Ashton Street,
Liverpool
L69 3GE
United Kingdon
T : +44 (0)151 794 5941
E : william.hope@liverpool.ac.uk
Dr Peter Warn,
Evotec,
William’s House,
Manchester Science Park,
Lloyd Street North,
Manchester,
M15 6SE
United Kingdom
T : +44 (0)161 820 3620
E : peter.warn@evotec.com

5. Manuscripts
Pharmacodynamics of vancomycin for CoNS infection: experimental
basis for optimal use of vancomycin in neonates
Ramos-Martin V, Johnson A, Livermore J, McEntee L, Goodwin J, Whalley S,
Docobo-Perez F, Felton T,W, Zhoa W, Jacqz-Aigrain E, Sharland M, Turner
MA, Hope WW
J Antimivrob Chemother. 2016 Jan 10
Pharmacodynamics of Isavuconazole in a Dynamic In Vitro Model of
Invasive Pulmonary Aspergillosis
Box H, Livermore J, Johnson A, McEntee L, Felton TW, Whalley S, Goodwin
J, Hope WW.
Antimicrob Agents Chemother. 2015 Oct 26
An invertebrate model to evaluate virulence in Aspergillus fumigatus:
the role of azole resistance.
Gomez-Lopez A, Forastiero A, Cendejas-Bueno E, Gregson L, Mellado E,
Howard SJ, Livermore JL,Hope WW, Cuenca-Estrella M.
Med Mycol. 2014 Apr 1;52(3):311-9.
Efficacy of an abbreviated induction regimen of amphotericin B
deoxycholate for cryptococcal meningoencephalitis: 3 days of therapy
is equivalent to 14 days.
Livermore J, Howard SJ, Sharp AD, Goodwin J, Gregson L, Felton T,
Schwartz JA, Walker C, Moser B, Müller W, Harrison TS, Perfect JR, Hope
WW.
MBio. 2014 Jan 28;5(1):e00725-13.
Impact of Bolus dosing versus continuous infusion of Piperacillin and
Tazobactam on the development of antimicrobial resistance in
Pseudomonas aeruginosa.
Felton TW, Goodwin J, O'Connor L, Sharp A, Gregson L, Livermore J,
Howard SJ, Neely MN, Hope WW.
Antimicrob Agents Chemother. 2013 Dec;57(12):5811-9.
Pharmacodynamics of liposomal amphotericin B and flucytosine for
cryptococcal meningoencephalitis: safe and effective regimens for
immunocompromised patients.
O'Connor L, Livermore J, Sharp AD, Goodwin J, Gregson L, Howard SJ,
Felton TW, Schwartz JA, Neely MN, Harrison TS, Perfect JR, Hope WW.
J Infect Dis. 2013 Jul 15;208(2):351-61.
Pharmacokinetics and pharmacodynamics of fluconazole for
cryptococcal meningoencephalitis: implications for antifungal therapy
and in vitro susceptibility breakpoints.

6. Sudan A, Livermore J, Howard SJ, Al-Nakeeb Z, Sharp A, Goodwin J,
Gregson L, Warn PA, Felton TW, Perfect JR, Harrison TS, Hope WW.
Antimicrob Agents Chemother. 2013 Jun;57(6):2793-800.
Pharmacokinetics and pharmacodynamics of anidulafungin for
experimental Candida endophthalmitis: insights into the utility of
echinocandins for treatment of a potentially sight-threatening infection.
Livermore JL, Felton TW, Abbott J, Sharp A, Goodwin J, Gregson L, Warn
PA, Howard SJ, Hope WW.
Antimicrob Agents Chemother. 2013 Jan;57(1):281-8.
Anidulafungin for Neonatal Hematogenous Candida
Meningoencephalitis: Identification of Candidate Regimens for Humans
Using a Translational Pharmacological Approach
Warn P, Livermore J, Howard S, Felton TW, Sharp A, Gregson L, Goodwin J,
Petraitiene R, Petraitis V, Cohen-Wolkowiez M, Walsh TJ, Benjamin DK Jr,
Hope WW. Antimicrob. Agents Chemother. 2012 Feb 56(2); 708-14
Pharmacodynamics of Echinocandins against Candida glabrata:
Requirement for Dosage Escalation to achieve Maximal Fungal Activity
in Neutropenic Hosts
Howard SJ, Livermore J, Sharp A, Goodwin J, Gregson L, Alastruey-Izquierdo
A, Perlin DS, Warn PA, Hope WW. Antimicrob. Agents Chemother. 2011
Oct 55(10); 4880 - 4887
Disseminated candidiasis caused by Candida albicans with amino acid
substitutions in Fks1 at position Ser645 cannot be successfully treated
with micafungin
Slater J, Howard S, Sharp A, Goodwin J, Gregson L, Alastruey-Izquierdo A,
Arendrup M, Warn P, Perlin D, Hope WW. Antimicrob. Agents Chemother.
2011 Jul. 55(7); 3075-83
Pharmacokinetics and pharmacodynamics of posaconazole for invasive
pulmonary aspergillosis: clinical implications for antifungal therapy
Howard S, Lestner JM, Sharp A, Gregson L, Goodwin J, Slater J, Majithiya
JB, Warn PA, Hope WW. J. Infect. Disease 2011 May 203(9); 1324-3
Pathogenicity of Aspergillus fumigatus Mutants Assessed in Galleria
mellonella Matches that of Mice
Slater J, Gregson L, Denning DW, Warn PA. Med. Mycol. 2011 Apr; 49
Suppl. 1; S107-13

7. Oral Presentations
22nd
European Congress of Clinical Microbiology and Infectious
Diseases (ECCMID) April 2012
“Pharmacokinetics and Pharmacodynamics of Anidulafungin for Candida
Endophthalmitis: Further Evidence for the Utility of Echinocandins for
Treatment of a Rapidly Sight-Threatening Infection “
6th
North West Microbiology Group Meeting September 2009
“Galleria mellonella as an alternative infection model to mice”
VII World Congress on Alternatives and Animal
Use in Life Sciences August 2009
“Galleria mellonella as a flexible mini-host system to study Virulence of
Aspergillus fumigatus and efficacy of antifungal drugs used in treatment”
British Society for Medical Mycology April 2008
“Quantifying fungal burden in an Invertebrate Model”
Fungal Research Trust 10th
Anniversary Aspergillus Website
Symposium March 2008
“Virulence in Aspergillus”
Respiratory Research Forum October2007
“Development of Non-Mammalian Host to Investigate Virulence,
Thermotolerance and Efficacy of Antifungal Drugs”
British Society for Medical Mycology March 2007
“Invertebrate Model demonstrates in vivo Relationship between
Growth Rate, Virulence and Temperature Tolerance in Aspergillus”
Poster Presentations
ICAAC, Denver, USA September 2013
ICAAC, San Francisco, USA (2 posters) September 2012
4th
Advances Against Aspergillosis, Rome, Italy January 2010
LASA Winter Meeting, London, UK Nov 2009
Centre for Integrative mammalian Biology Showcase Symposium June 2009
NC3Rs Parliamentary Poster Event, House of Lords, London, UK March 2009
ICAAC, Washington, DC Oct 2008
3rd
Advances Against Aspergillosis, Miami, Florida January 2008
British Society for Medical Mycology, Leeds, UK March 2007
Focus on Fungal Infections, San Diego, Ca March 2007